WHITECOAT Strategies, LLC, Opens for Business, Challenges Clients to "Put More Life in Your Science"
04 févr. 2008 14h32 HE
|
WHITECOAT Strategies, LLC
WASHINGTON, DC--(Marketwire - February 4, 2008) - With over 100 years of collective staff
experience, WHITECOAT Strategies, LLC, opens today to serve science and
technology driven clients, including...
Alcon Reports Strong Fourth Quarter and Full-year 2002 Results
20 févr. 2003 09h02 HE
|
Nestle S.A.
HUNENBERG, Switzerland, Feb. 20, 2003 (PRIMEZONE) -- Alcon, Inc. (NYSE:ACL) reported global sales of USD 749.2 million for the fourth quarter of 2002, an increase of 11.7 percent over sales in the...
Novartis Meets Full-Year Double-Digit Sales Growth Objective with Strong Operating Performance in 2002
23 janv. 2003 01h52 HE
|
Novartis
BASEL, Switzerland, Jan. 23, 2003 (PRIMEZONE) -- Novartis (NYSE:NVS):
-- Group sales up 11% in local currencies (2% in CHF) thanks to strong
volume growth in Pharmaceuticals and Generics
...
Spanish Distribution Firm Turns to ReadSoft for Invoices Capture
02 mai 2002 04h09 HE
|
ReadSoft
STOCKHOLM, Sweden, May 2, 2002 (PRIMEZONE) -- ReadSoft has closed a deal with the largest Pharmaceutical Distribution Group in Spain, Unycop, who will use ReadSoft's software INVOICES to process...
Medivir: Interim Report, 1 January - 31 March 2002 (with link)
26 avr. 2002 05h33 HE
|
Medivir
HUDDINGE, Sweden, April 26, 2002 (PRIMEZONE) -- Medivir:
- MIV-606 against shingles: US market rights outlicensed to Reliant
Pharmaceuticals, raising a SEK 50 m up-front payment. Medivir...
Pharmexa A/S: Inoxell Receives Acceptance of its Scaffold Technology Patent from the European Patent Office
24 avr. 2002 11h16 HE
|
Pharmexa A/S
HORSHOLM, Denmark, April 24, 2002 (PRIMEZONE) -- Pharmexa's 83.3% owned subsidiary Inoxell A/S today announced that the European Patent Office has issued an acceptance of Inoxell's patent on its...
CeNeS Announces Preliminary Results for the Year- Ended December 31, 2001 (with link)
27 mars 2002 03h16 HE
|
CeNeS Pharmaceuticals Plc
CAMBRIDGE, U.K., March 27, 2002 (PRIMEZONE) -- CeNeS Pharmaceuticals plc (LSE:CEN) today announced its results for the year ended Dec. 31, 2001 and an update on its restructuring plan.
Key events...
Solvay Group: Final 2001 Results; Confirmation of Net Current Earnings of EUR 403 million; Net Dividend Maintained at EUR 1.70 per Share
22 mars 2002 03h03 HE
|
CompanynewsGroup
BRUSSELS, Belgium, March 22, 2002 (PRIMEZONE) -- Results of the Solvay Group (Euronext Brussels:SOLB) (Xetra:SOL) and the parent company, Solvay S.A.
As announced on February 18, 2002, the Solvay...
BioPhausia: Year end report 2001 (with link)
27 févr. 2002 13h15 HE
|
BioPhausia
UPPSALA, Sweden, February 27, 2002 (PRIMEZONE) -- BioPhausia reports year-end results and significant events.
-- Sales amounted to SEK 2.071.000 (SEK 975.000)
-- Rights for RescueFlow(r)...
Tripep AB publ: Year-End 2001 (with links)
25 janv. 2002 04h15 HE
|
Tripep
HUDDINGE, Sweden, Jan. 25, 2002 (PRIMEZONE) -- Tripep AB (publ):
-- New plan adopted, entailing three areas of operation for Tripep:
-- the HIV-inhibiting pharmaceutical GPG(r),
-- a...